PURPOSE: Salvage options for recurrent high-grade gliomas (HGGs) are limited by cumulative toxicity and limited efficacy despite advances in chemotherapeutic and radiotherapeutic techniques. Previous studies have reported encouraging survival results and favorable toxicity with fractionated stereotactic radiotherapy, and small studies have shown similar benefit using a shortened course of hypofractionated stereotactic radiation therapy (H-SRT). We sought to determine the efficacy and toxicity profile of H-SRT alone or in addition to repeat craniotomy or concomitant chemotherapy. PATIENTS AND METHODS: Between 1994 and 2008, 147 patients with recurrent HGG were treated with H-SRT (median dose, 35 Gy in 3.5-Gy fractions). Cox regression models were used to analyze survival outcomes. Variables included age, surgery before H-SRT, time to first recurrence, reirradiation dose, inclusion of chemotherapy with H-SRT, and gross tumor volume (GTV). RESULTS: Younger age (P = .001), smaller GTV (P = .025), and shorter time between diagnosis and recurrence (P = .034) were associated with improvement in survival from H-SRT. Doses of radiation > or = 35 Gy approached significance (P = .07). There was no significant benefit of surgical resection or chemotherapy in this population when analysis was controlled for other prognostic factors. CONCLUSION: H-SRT was well tolerated and resulted in a median survival time of 11 months after H-SRT, independent of re-operation or concomitant chemotherapy. Patients who experienced recurrence within 6 months after initial treatment had an excellent response and should not be disqualified from H-SRT. This is the largest series to examine the efficacy and tolerability of H-SRT in recurrent HGG.
PURPOSE: Salvage options for recurrent high-grade gliomas (HGGs) are limited by cumulative toxicity and limited efficacy despite advances in chemotherapeutic and radiotherapeutic techniques. Previous studies have reported encouraging survival results and favorable toxicity with fractionated stereotactic radiotherapy, and small studies have shown similar benefit using a shortened course of hypofractionated stereotactic radiation therapy (H-SRT). We sought to determine the efficacy and toxicity profile of H-SRT alone or in addition to repeat craniotomy or concomitant chemotherapy. PATIENTS AND METHODS: Between 1994 and 2008, 147 patients with recurrent HGG were treated with H-SRT (median dose, 35 Gy in 3.5-Gy fractions). Cox regression models were used to analyze survival outcomes. Variables included age, surgery before H-SRT, time to first recurrence, reirradiation dose, inclusion of chemotherapy with H-SRT, and gross tumor volume (GTV). RESULTS: Younger age (P = .001), smaller GTV (P = .025), and shorter time between diagnosis and recurrence (P = .034) were associated with improvement in survival from H-SRT. Doses of radiation > or = 35 Gy approached significance (P = .07). There was no significant benefit of surgical resection or chemotherapy in this population when analysis was controlled for other prognostic factors. CONCLUSION: H-SRT was well tolerated and resulted in a median survival time of 11 months after H-SRT, independent of re-operation or concomitant chemotherapy. Patients who experienced recurrence within 6 months after initial treatment had an excellent response and should not be disqualified from H-SRT. This is the largest series to examine the efficacy and tolerability of H-SRT in recurrent HGG.
Authors: David A Larson; Michael Prados; Kathleen R Lamborn; Vernon Smith; Penny K Sneed; Susan Chang; Kelly M Nicholas; William M Wara; Daniel Devriendt; Sandeep Kunwar; Mitch Berger; Michael W McDermott Journal: Int J Radiat Oncol Biol Phys Date: 2002-12-01 Impact factor: 7.038
Authors: S A Leibel; P H Gutin; W M Wara; P S Silver; D A Larson; M S Edwards; S A Lamb; B Ham; K A Weaver; C Barnett Journal: Int J Radiat Oncol Biol Phys Date: 1989-12 Impact factor: 7.038
Authors: P H Gutin; M D Prados; T L Phillips; W M Wara; D A Larson; S A Leibel; P K Sneed; V A Levin; K A Weaver; P Silver Journal: Int J Radiat Oncol Biol Phys Date: 1991-08 Impact factor: 7.038
Authors: R C Florell; D R Macdonald; W D Irish; M Bernstein; S A Leibel; P H Gutin; J G Cairncross Journal: J Neurosurg Date: 1992-02 Impact factor: 5.115
Authors: Robert B Den; Mitchell Kamrava; Zhi Sheng; Maria Werner-Wasik; Erin Dougherty; Michelle Marinucchi; Yaacov R Lawrence; Sarah Hegarty; Terry Hyslop; David W Andrews; Jon Glass; David P Friedman; Michael R Green; Kevin Camphausen; Adam P Dicker Journal: Int J Radiat Oncol Biol Phys Date: 2012-06-09 Impact factor: 7.038
Authors: T Hundsberger; A F Hottinger; U Roelcke; P Roth; D Migliorini; P Y Dietrich; K Conen; G Pesce; E Hermann; A Pica; M W Gross; D Brügge; L Plasswilm; M Weller; P M Putora Journal: J Neurooncol Date: 2015-10-12 Impact factor: 4.130
Authors: Debra A Goldman; Koos Hovinga; Anne S Reiner; Yoshua Esquenazi; Viviane Tabar; Katherine S Panageas Journal: J Neurosurg Date: 2018-11-01 Impact factor: 5.115
Authors: Eun Young Kim; Raphael Yechieli; Jin Koo Kim; Tom Mikkelsen; Steven N Kalkanis; Jack Rock; Mark Rosenblum; Samuel Ryu Journal: J Neurooncol Date: 2013-10-31 Impact factor: 4.130
Authors: Joshua T McKenzie; Jess N Guarnaschelli; Achala S Vagal; Ronald E Warnick; John C Breneman Journal: J Neurooncol Date: 2013-04-16 Impact factor: 4.130